blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2609100

EP2609100 - FUROPYRIDINE DERIVATIVES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  29.04.2016
Database last updated on 04.06.2024
Most recent event   Tooltip19.10.2018Lapse of the patent in a contracting state
New state(s): AL		published on 21.11.2018  [2018/47]
Applicant(s)For all designated states
Merck Patent GmbH
Frankfurter Strasse 250
64293 Darmstadt / DE
[2013/27]
Inventor(s)01 / BURGDORF, Lars
Gabelsbergerstrasse 21
60389 Frankfurt am Main / DE
02 / SCHULTZ, Melanie
Wienerstrasse 63
64287 Darmstadt / DE
03 / ROSS, Tatjana
Taunusblick 13
65760 Eschborn / DE
04 / HODOUS, Brian
250 Chestnut Street
Cambridge MA 02139 / US
05 / POTNICK, Justin
53 Conant Street
Acton, MA 01720 / US
06 / SUTTON, Amanda E.
4 Triphammer Road
Hingham Massachusetts 02043 / US
07 / HUCK, Bayard R.
50 Woodmere Drive
Sudbury Massachusetts 01776 / US
 [2013/32]
Former [2013/28]01 / BURGDORF, Lars
Gabelsbergerstrasse 21
60389 Frankfurt am Main / DE
02 / SCHULTZ, Melanie
Wienerstrasse 63
64287 Darmstadt / DE
03 / HOFMANN, Tatjana
Josef-Traxel-Weg 4
55128 Mainz / DE
04 / HODOUS, Brian
250 Chestnut Street
Cambridge MA 02139 / US
05 / POTNICK, Justin
53 Conant Street
Acton, MA 01720 / US
06 / SUTTON, Amanda E.
4 Triphammer Road
Hingham Massachusetts 02043 / US
07 / HUCK, Bayard R.
50 Woodmere Drive
Sudbury Massachusetts 01776 / US
Former [2013/27]01 / BURGDORF, Lars
Gabelsbergerstrasse 21
60389 Frankfurt am Main / DE
02 / SCHULTZ, Melanie
Wienerstrasse 63
64287 Darmstadt / DE
03 / HOFMANN, Tatjana
Josef-Traxel-Weg 4
55128 Mainz / DE
04 / HODOUS, Brian
250 Chestnut Street
Cambridge MA 02139 / US
05 / POTNICK, Justin
499 Boston Rd.
Unit 1220
Billerica Massachusetts 01821 / US
06 / SUTTON, Amanda E.
4 Triphammer Road
Hingham Massachusetts 02043 / US
07 / HUCK, Bayard R.
50 Woodmere Drive
Sudbury Massachusetts 01776 / US
Application number, filing date11738631.829.07.2011
WO2011EP03831
Priority number, dateEP2010000892827.08.2010         Original published format: EP 10008928
[2013/27]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2012025187
Date:01.03.2012
Language:EN
[2012/09]
Type: A2 Application without search report 
No.:EP2609100
Date:03.07.2013
Language:EN
The application published by WIPO in one of the EPO official languages on 01.03.2012 takes the place of the publication of the European patent application.
[2013/27]
Type: B1 Patent specification 
No.:EP2609100
Date:24.06.2015
Language:EN
[2015/26]
Search report(s)International search report - published on:EP21.06.2012
ClassificationIPC:A61K45/06, A61K31/4709, A61K31/496, A61K31/506, A61K31/5377, A61K31/5383, C07D491/048, C07D519/00, C07D491/04, A61K31/4355
[2015/08]
CPC:
C07D491/048 (EP,US); C07D491/04 (EP,KR,US); A61K31/4355 (EP,KR,US);
A61K31/4709 (EP,US); A61K31/496 (EP,US); A61K31/506 (EP,US);
A61K31/5377 (EP,US); A61K31/5383 (EP,US); A61K45/06 (US);
A61P11/00 (EP); A61P11/02 (EP); A61P11/06 (EP);
A61P15/08 (EP); A61P19/02 (EP); A61P25/00 (EP);
A61P29/00 (EP); A61P3/00 (EP); A61P31/00 (EP);
A61P35/00 (EP); A61P35/02 (EP); A61P37/02 (EP);
A61P37/06 (EP); A61P37/08 (EP); A61P7/02 (EP);
A61P9/00 (EP); C07D519/00 (EP,US) (-)
Former IPC [2013/27]C07D491/04, A61K31/4355
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2013/27]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:FUROPYRIDINDERIVATE[2013/27]
English:FUROPYRIDINE DERIVATIVES[2013/27]
French:DÉRIVÉS DE FUROPYRIDINE[2013/27]
Entry into regional phase09.01.2013National basic fee paid 
09.01.2013Designation fee(s) paid 
09.01.2013Examination fee paid 
Examination procedure09.01.2013Examination requested  [2013/27]
08.10.2013Amendment by applicant (claims and/or description)
30.09.2014Despatch of a communication from the examining division (Time limit: M02)
10.10.2014Reply to a communication from the examining division
06.03.2015Communication of intention to grant the patent
12.05.2015Fee for grant paid
12.05.2015Fee for publishing/printing paid
12.05.2015Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  30.09.2014
Opposition(s)29.03.2016No opposition filed within time limit [2016/22]
Fees paidRenewal fee
10.07.2013Renewal fee patent year 03
14.07.2014Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU29.07.2011
AL24.06.2015
AT24.06.2015
BE24.06.2015
CY24.06.2015
CZ24.06.2015
DK24.06.2015
EE24.06.2015
FI24.06.2015
HR24.06.2015
LT24.06.2015
LV24.06.2015
MC24.06.2015
MK24.06.2015
MT24.06.2015
NL24.06.2015
PL24.06.2015
RO24.06.2015
RS24.06.2015
SE24.06.2015
SI24.06.2015
SK24.06.2015
SM24.06.2015
TR24.06.2015
IE29.07.2015
LU29.07.2015
BG24.09.2015
NO24.09.2015
GR25.09.2015
IS24.10.2015
PT26.10.2015
[2018/47]
Former [2018/31]HU29.07.2011
AT24.06.2015
BE24.06.2015
CY24.06.2015
CZ24.06.2015
DK24.06.2015
EE24.06.2015
FI24.06.2015
HR24.06.2015
LT24.06.2015
LV24.06.2015
MC24.06.2015
MK24.06.2015
MT24.06.2015
NL24.06.2015
PL24.06.2015
RO24.06.2015
RS24.06.2015
SE24.06.2015
SI24.06.2015
SK24.06.2015
SM24.06.2015
TR24.06.2015
IE29.07.2015
LU29.07.2015
BG24.09.2015
NO24.09.2015
GR25.09.2015
IS24.10.2015
PT26.10.2015
Former [2018/02]HU29.07.2011
AT24.06.2015
BE24.06.2015
CY24.06.2015
CZ24.06.2015
DK24.06.2015
EE24.06.2015
FI24.06.2015
HR24.06.2015
LT24.06.2015
LV24.06.2015
MC24.06.2015
MT24.06.2015
NL24.06.2015
PL24.06.2015
RO24.06.2015
RS24.06.2015
SE24.06.2015
SI24.06.2015
SK24.06.2015
SM24.06.2015
IE29.07.2015
LU29.07.2015
BG24.09.2015
NO24.09.2015
GR25.09.2015
IS24.10.2015
PT26.10.2015
Former [2017/39]HU29.07.2011
AT24.06.2015
BE24.06.2015
CY24.06.2015
CZ24.06.2015
DK24.06.2015
EE24.06.2015
FI24.06.2015
HR24.06.2015
LT24.06.2015
LV24.06.2015
MC24.06.2015
MT24.06.2015
NL24.06.2015
PL24.06.2015
RO24.06.2015
RS24.06.2015
SE24.06.2015
SI24.06.2015
SK24.06.2015
SM24.06.2015
IE29.07.2015
BG24.09.2015
NO24.09.2015
GR25.09.2015
IS24.10.2015
PT26.10.2015
Former [2017/22]AT24.06.2015
BE24.06.2015
CZ24.06.2015
DK24.06.2015
EE24.06.2015
FI24.06.2015
HR24.06.2015
LT24.06.2015
LV24.06.2015
MC24.06.2015
MT24.06.2015
PL24.06.2015
RO24.06.2015
RS24.06.2015
SI24.06.2015
SK24.06.2015
IE29.07.2015
BG24.09.2015
NO24.09.2015
GR25.09.2015
IS24.10.2015
PT26.10.2015
Former [2017/03]AT24.06.2015
BE24.06.2015
CZ24.06.2015
DK24.06.2015
EE24.06.2015
FI24.06.2015
HR24.06.2015
LT24.06.2015
LV24.06.2015
MC24.06.2015
PL24.06.2015
RO24.06.2015
RS24.06.2015
SI24.06.2015
SK24.06.2015
IE29.07.2015
BG24.09.2015
NO24.09.2015
GR25.09.2015
IS24.10.2015
PT26.10.2015
Former [2016/36]AT24.06.2015
CZ24.06.2015
DK24.06.2015
EE24.06.2015
FI24.06.2015
HR24.06.2015
LT24.06.2015
LV24.06.2015
MC24.06.2015
PL24.06.2015
RO24.06.2015
RS24.06.2015
SI24.06.2015
SK24.06.2015
IE29.07.2015
BG24.09.2015
NO24.09.2015
GR25.09.2015
IS24.10.2015
PT26.10.2015
Former [2016/33]AT24.06.2015
CZ24.06.2015
DK24.06.2015
EE24.06.2015
FI24.06.2015
HR24.06.2015
LT24.06.2015
LV24.06.2015
MC24.06.2015
PL24.06.2015
RO24.06.2015
RS24.06.2015
SK24.06.2015
IE29.07.2015
BG24.09.2015
NO24.09.2015
GR25.09.2015
IS24.10.2015
PT26.10.2015
Former [2016/20]AT24.06.2015
CZ24.06.2015
DK24.06.2015
EE24.06.2015
FI24.06.2015
HR24.06.2015
LT24.06.2015
LV24.06.2015
MC24.06.2015
PL24.06.2015
RO24.06.2015
RS24.06.2015
SK24.06.2015
BG24.09.2015
NO24.09.2015
GR25.09.2015
IS24.10.2015
PT26.10.2015
Former [2016/18]AT24.06.2015
CZ24.06.2015
EE24.06.2015
FI24.06.2015
HR24.06.2015
LT24.06.2015
LV24.06.2015
MC24.06.2015
PL24.06.2015
RO24.06.2015
RS24.06.2015
SK24.06.2015
BG24.09.2015
NO24.09.2015
GR25.09.2015
IS24.10.2015
PT26.10.2015
Former [2016/11]AT24.06.2015
CZ24.06.2015
EE24.06.2015
FI24.06.2015
HR24.06.2015
LT24.06.2015
LV24.06.2015
PL24.06.2015
RO24.06.2015
RS24.06.2015
SK24.06.2015
BG24.09.2015
NO24.09.2015
GR25.09.2015
IS24.10.2015
PT26.10.2015
Former [2016/10]CZ24.06.2015
EE24.06.2015
FI24.06.2015
HR24.06.2015
LT24.06.2015
LV24.06.2015
PL24.06.2015
RO24.06.2015
RS24.06.2015
SK24.06.2015
BG24.09.2015
NO24.09.2015
GR25.09.2015
IS24.10.2015
PT26.10.2015
Former [2016/09]EE24.06.2015
FI24.06.2015
HR24.06.2015
LT24.06.2015
LV24.06.2015
RS24.06.2015
BG24.09.2015
NO24.09.2015
GR25.09.2015
Former [2015/50]FI24.06.2015
HR24.06.2015
LT24.06.2015
LV24.06.2015
RS24.06.2015
BG24.09.2015
NO24.09.2015
GR25.09.2015
Former [2015/49]FI24.06.2015
HR24.06.2015
LT24.06.2015
LV24.06.2015
RS24.06.2015
NO24.09.2015
GR25.09.2015
Cited inInternational search[I]WO9940091  (AMGEN INC [US]) [I] 1-17 * page 13, line 5 - page 29, line 28; page 30, line 4 - page 34, line 9; examples 228, 230, 231; figure 1B *;
 [A]US2002004511  (LUZZIO MICHAEL JOSEPH [US], et al) [A] 1-17 * [0008]-[0018]; [0180]-[0189]; examples *
by applicantWO2008118823
 WO2009136995
 WO2010027500
    - J. A.TAYLOR ET AL., MOLEC. AND CELL BIOL, (1995), vol. 15, pages 4149 - 4157
    - TURNER, M., SCHWEIGHOFFER, E., COLUCCI, F., DI SANTO, J.P., TYBULEWICZ, V.L., "Tyrosine kinase SYK: essential functions for immunoreceptor signalling", IMMUNOL TODAY, (2000), vol. 21, doi:doi:10.1016/S0167-5699(99)01574-1, pages 148 - 154, XP004202530

DOI:   http://dx.doi.org/10.1016/S0167-5699(99)01574-1
    - GHOSH, D., TSOKOS, G.C., "Spleen tyrosine kinase: an Src family of non-receptor kinase has multiple functions and represents a valuable therapeutic target in the treatment of autoimmune and inflammatory diseases", AUTOIMMUNITY, vol. 43, pages 48 - 55
    - LINDVALL, J.M. ET AL., "Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling", IMMUNOL REV, (2005), vol. 203, pages 200 - 215
    - GILFILLAN, A.M., TKACZYK, C., "Integrated signalling pathways for mast-cell activation", NAT REV IMMUNOL, (2006), vol. 6, pages 218 - 230
    - GOMEZ, G., SCHWARTZ, L., KEPLEY, C., "Syk deficiency in human nonreleaser lung mast cells", CLIN IMMUNOL, (2007), vol. 125, doi:doi:10.1016/j.clim.2007.06.006, pages 112 - 115, XP022240717

DOI:   http://dx.doi.org/10.1016/j.clim.2007.06.006
    - KEPLEY, C.L., YOUSSEF, L., ANDREWS, R.P., WILSON, B.S., OLIVER, J.M., "Syk deficiency in nonreleaser basophils", J ALLERGY CLIN IMMUNOL, (1999), vol. 104, doi:doi:10.1016/S0091-6749(99)70367-2, pages 279 - 284, XP027464691

DOI:   http://dx.doi.org/10.1016/S0091-6749(99)70367-2
    - ZOU, W. ET AL., "Syk, c-Src, the alphavbeta3 integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption", J CELL BIOL, (2007), vol. 176, pages 877 - 888
    - REEVE, J.L. ET AL., "SLP-76 couples Syk to the osteoclast cytoskeleton", J IMMUNOL, (2009), vol. 183, pages 1804 - 1812
    - KLARESKOG, L., CATRINA, A.I., PAGET, S., "Rheumatoid arthritis", LANCET, (2009), vol. 373, pages 659 - 672
    - WONG, B.R., GROSSBARD, E.B., PAYAN, D.G., MASUDA, E.S., "Targeting Syk as a treatment for allergic and autoimmune disorders", EXPERT OPIN INVESTIG DRUGS, (2004), vol. 13, pages 743 - 762, XP002628811
    - BRASELMANN, S. ET AL., "R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation", J PHARMACOL EXP THER, (2006), vol. 319, doi:doi:10.1124/jpet.106.109058, pages 998 - 1008, XP002468270

DOI:   http://dx.doi.org/10.1124/jpet.106.109058
    - PINE, P.R. ET AL., "Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor", CLIN IMMUNOL, (2007), vol. 124, doi:doi:10.1016/j.clim.2007.03.543, pages 244 - 257, XP022202330

DOI:   http://dx.doi.org/10.1016/j.clim.2007.03.543
    - TOMILLERO, A., MORAL, M.A., "Gateways to clinical trials", METHODS FIND EXP CLIN PHARMACOL, (2009), vol. 31, pages 47 - 57
    - BAJPAI, M. FOSTAMATINIB, "a Syk inhibitor prodrug for the treatment of inflammatory diseases", DRUGS, (2009), vol. 12, pages 174 - 185, XP009122338
    - WEINBLATT, M.E. ET AL., "Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial", ARTHRITIS RHEUM, (2008), vol. 58, pages 3309 - 3318
    - KRISHNAN, S., WARKE, V.G., NAMBIAR, M.P., TSOKOS, G.C., FARBER, D.L., "The FcR gamma subunit and Syk kinase replace the CD3 zeta-chain and ZAP-70 kinase in the TCR signaling complex of human effector CD4 T cells", J IMMUNOL, (2003), vol. 170, pages 4189 - 4195
    - KRISHNAN, S. ET AL., "Differential expression and molecular associations of Syk in systemic lupus erythematosus T cells", J IMMUNOL, (2008), vol. 181, pages 8145 - 8152
    - BAHJAT, F.R. ET AL., "An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus", ARTHRITIS RHEUM, (2008), vol. 58, doi:doi:10.1002/art.23428, pages 1433 - 1444, XP002572834

DOI:   http://dx.doi.org/10.1002/art.23428
    - ENYEDY, E.J. ET AL., "Fc epsilon receptor type I gamma chain replaces the deficient T cell receptor zeta chain in T cells of patients with systemic lupus erythematosus", ARTHRITIS RHEUM, (2001), vol. 44, pages 1114 - 1121
    - PERL, A., "Systems biology of lupus: mapping the impact of genomic and environmental factors on gene expression signatures, cellular signaling, metabolic pathways, hormonal and cytokine imbalance, and selecting targets for treatment", AUTOIMMUNITY, vol. 43, pages 32 - 47
    - SMITH, J. ET AL., "A spleen tyrosine kinase inhibitor reduces the severity of established glomerulonephritis", J AM SOC NEPHROL, vol. 21, pages 231 - 236
    - SANDERSON, M.P., GELLING, S.J., RIPPMANN, J.F., SCHNAPP, A., "Comparison of the anti-allergic activity of Syk inhibitors with optimized Syk siRNAs in FcepsilonRl-activated RBL-2H3 basophilic cells", CELL IMMUNOL, vol. 262, doi:doi:10.1016/j.cellimm.2009.12.004, pages 28 - 34, XP026930423

DOI:   http://dx.doi.org/10.1016/j.cellimm.2009.12.004
    - PODOLANCZUK, A., LAZARUS, A.H., CROW, A.R., GROSSBARD, E., BUSSEL, J.B., "Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk", BLOOD, (2009), vol. 113, pages 3154 - 3160
    - BAJPAI, M., CHOPRA, P., DASTIDAR, S.G., RAY, A., "Spleen tyrosine kinase: a novel target for therapeutic intervention of rheumatoid arthritis", EXPERT OPIN INVESTIG DRUGS, (2008), vol. 17, pages 641 - 659
    - FRIEDBERG, J.W. ET AL., "Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia", BLOOD, vol. 115, doi:doi:10.1182/blood-2009-08-236471, pages 2578 - 2585, XP055213215

DOI:   http://dx.doi.org/10.1182/blood-2009-08-236471
    - GAO, C. ET AL., "Eptifibatide-induced thrombocytopenia and thrombosis in humans require FcgammaRlla and the integrin beta3 cytoplasmic domain", J CLIN INVEST, (2009), vol. 119, pages 504 - 511
    - MARJON, K.D., MARNELL, L.L., MOLD, C., DU CLOS, T.W., "Macrophages activated by C-reactive protein through Fc gamma RI transfer suppression of immune thrombocytopenia", J IMMUNOL, (2009), vol. 182, pages 1397 - 1403
    - CHEN, L. ET AL., "SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma", BLOOD, (2008), vol. 111, pages 2230 - 2237
    - PECHLOFF, K. ET AL., "The fusion kinase ITK-SYK mimics a T cell receptor signal and drives oncogenesis in conditional mouse models of peripheral T cell lymphoma", J EXP MED, (2009), vol. 207, doi:doi:10.1084/jem.20092042, pages 1031 - 1044, XP055027893

DOI:   http://dx.doi.org/10.1084/jem.20092042
    - UCKUN, F.M., EK, R.O., JAN, S.T., CHEN, C.L., QAZI, S., "Targeting SYK kinase-dependent anti-apoptotic resistance pathway in B-lineage acute lymphoblastic leukaemia (ALL) cells with a potent SYK inhibitory pentapeptide mimic", BR J HAEMATOL, (2010), vol. 149, pages 508 - 517
    - WILCOX, R.A. ET AL., "Inhibition of Syk protein tyrosine kinase induces apoptosis and blocks proliferation in T-cell non-Hodgkin's lymphoma cell lines", LEUKEMIA, (2009), vol. 24, pages 229 - 232
    - FELDMAN, A.L. ET AL., "Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas", LEUKEMIA, (2008), vol. 22, doi:doi:10.1038/leu.2008.77, pages 1139 - 1143, XP055197930

DOI:   http://dx.doi.org/10.1038/leu.2008.77
    - WANG, L. ET AL., "Alternative splicing disrupts a nuclear localization signal in spleen tyrosine kinase that is required for invasion suppression in breast cancer", CANCER RES, (2003), vol. 63, pages 4724 - 4730
    - M. TURNER ET AL., IMMUNOLOGY TODAY, (2000), vol. 21, page 148
    - 0. T. CHAN ET AL., IMMUNOLOGICAL, (1999), vol. 169, pages 107 - 121
    - A. GAUSE ET AL., BIODRUGS, (2001), vol. 15, no. 2, pages 73 - 79
    - C. K. COMBS ET AL., J. NEUROSCL, (1999), vol. 19, pages 928 - 939
    - Y. KUNO ET AL., BLOOD, (2001), vol. 97, pages 1050 - 1055
    - FRANK, MOL. MED., (1999), vol. 5, no. 432, page 456
    - SEIDEL ET AL., ONCOGENE, (2000), vol. 19, pages 2645 - 2656
    - GILLILAND ET AL., BLOOD, (2002), vol. 100, pages 1532 - 1542
    - STIREWALT ET AL., NAT. REV. CANCER, (2003), vol. 3, pages 650 - 665
    - MALEMPATI ET AL., BLOOD, (2004), vol. 104, page 11
    - LEVIS ET AL., INT. J. HEMATOL, (2005), vol. 52, pages 100 - 107
    - LEVIS ET AL., BLOOD, (2002), vol. 99, pages 3885 - 3891
    - KELLY ET AL., CANCER CELL, (2002), vol. 1, pages 421 - 432
    - WEISBERG ET AL., CANCER CELL, (2002), vol. 1, pages 433 - 443
    - YEE ET AL., BLOOD, (2002), vol. 100, pages 2941 - 2949
    - KUROSAKI, CURR OP IMM, (2000), pages 276 - 281
    - SCHAEFFER, SCHWARTZBERG, CURR OP LMM, (2000), pages 282 - 288
    - KHWAJA ET AL., EMBO, (1997), vol. 16, pages 2783 - 93
    - WHITE ET AL., ONCOGENE, (2001), vol. 20, pages 7064 - 7072
    - STEPHENS ET AL., BIOCHEMICAL J., (2000), vol. 351, pages 95 - 105
    - ALESSI ET AL., FEBS LETT., (1996), vol. 399, no. 3, pages 333 - 338
    - CAMPOS-GONZ6LEZ, R., GLENNEY, JR., J.R., J. BIOL. CHEM., (1992), vol. 267, page 14535
    - SORG ET AL., J. OF. BIOMOLECULAR SCREENING, (2002), vol. 7, pages 11 - 19
    - SILLS ET AL., J. OF BIOMOLECULAR SCREENING, (2002), pages 191 - 214
    - W. J. COATES, A. MCKILLOP, SYNTHESIS, (1993), pages 334 - 342
    - PHARMACEUTICAL RESEARCH, (1986), vol. 3, no. 6, page 318
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.